Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Portfolio Pulse from
Clene Inc. has partnered with APST Research to analyze the impact of CNM-Au8 on NfL biomarkers in ALS patients, supporting FDA recommendations. This collaboration aims to provide robust data for Clene's upcoming New Drug Application in 2025.
February 25, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene Inc. has entered into a partnership with APST Research to support FDA recommendations by analyzing CNM-Au8's impact on NfL biomarkers in ALS patients. This is a strategic move to strengthen their New Drug Application planned for 2025.
The partnership with APST Research is crucial for Clene as it provides the necessary data to support FDA recommendations, which is a positive step towards their NDA submission. This could enhance investor confidence and potentially lead to a positive short-term impact on CLNN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100